1.Evaluation of CAP test system for allergen-specific IgE assay
Chinese Journal of Clinical Laboratory Science 2006;0(02):-
Objective To evaluate the validity and predictive value of CAP specific IgE test system.Methods Five allergen-specific IgEs,i.e.,specific IgE to mites,mugwort pollens,hop pollens,cat epithelium and dander,and Alternaria alternate,were tested in selected randomly allergic and non-allergic patients by using CAP system.Results In 957 tests the sensitivity of specific IgE to the 5 allergens was 99.0%,97.9%,91.7%,93.5% and 85.5%,and the specificity was 96.2%,95.8%,93.0%,97.0% and 91.7%.The positive and negative predictive values were greater than 94% and 80% respectively.Conclusion CAP system is of great potential value for diagnosis of allergens.
2.SHORT-TERM ANTI-HBV EFFICACY OF FOSCARNET SODIUM
Ruiqi ZHANG ; Xiaohui MIAO ; Xion CAI
Medical Journal of Chinese People's Liberation Army 1982;0(03):-
To investigate the short term anti HBV efficacy of foscarnet sodium, sixty seven patients with various types of chronic hepatitis B were randomly divided into two groups. The experimental group (47 cases) was assigned to receive foscarnet sodium 3 0g by intravenous infusion twice daily in addition to general liver protective medicine for 15 days. The control group (20 cases) was treated with regular liver protective medicine only. The quantity of HBV DNA was measured with equivalent competitive PCR combining with DNA hybridization quantitative detection technique before and after treatment (once a week). The HBV markers and liver functions were also tested before and after treatment. In antiviral therapy group, the patients with different types of hepatitis B had their liver functions improved. HBV DNA in 13 patients became negative by PCR. Two of HBeAg positive patients became sero converted. Foscarnet sodium can inhibit HBV efficiently and quickly. The replication of HBV DNA can be greatly suppressed in the first week but without significant change in the second week in some cases. Foscarnet can be one of the drugs of choice in a combined therapy or as the initial drug in a sequential therapeutic regime.
3.FEVER OF UNKNOWN ORIGIN: A RETROSPECTIVE ANALYSIS OF 107 CLINICAL CASES
Wu NI ; Xiaohui MIAO ; Ruiqi ZHANG
Medical Journal of Chinese People's Liberation Army 2001;0(10):-
To investigate causes and clinical picture of fever of unknown origin (FUO), and to sum up the experiences in diagnosis of FUO, the medical records of 107 patients with FUO were reviewed retrospectively. Specific causes were identified in 99. 1% of these patients, including infections in 50 patients(46. 7%) , rheumatic problems in 22(20. 6%) and malignancies in 17(15. 9%). The main pathogens responsible for the infections were pyogenic bacteria(72. 0% , 36/50) and M tuberculosis (18. 0% , 9/50), mostly extrapulmonary. Lymphatic and he-mopoietic tissue neoplasms were the main forms of malignancy (88. 2%, 15/17), including histiocytosis, malignant lymphoma and leukemia. Drug fever was another common cause of FUO, accounting for 8. 4% in our series.
4.Staining Improvement for Trichomonas vaginalis Specimen
Shuilian SU ; Ruiqi ZHANG ; Guifeng CHEN
Chinese Journal of Parasitology and Parasitic Diseases 1987;0(01):-
By changing/improving the preparation,ratio,concentration and pH value of the staining solution,the cultured specimen of Trichomonas vaginalis was better observed.Different parts of the parasite are clearly viewed,and the method is simple,prompt and effective for staining and preservation.
5.Enhancing effect of astragalus polysaccharide on the immune function in cytoxan-induced immunosuppressed mice
Ruiqi ZHANG ; Zhengli CHEN ; Qihui LUO
Acta Laboratorium Animalis Scientia Sinica 2015;(4):389-394
Objective To explore the regulatory effect of astragalus polysaccharide ( APS) on immune function in immunosuppressed mice, and to establish a set of feasible indexes of immunological regulation and evaluation system of pol-ysaccharides.Methods Both Cytoxan ( CTX)-induced immunosuppressed mice and normal mice were treated with astrag-alus polysaccharide ( APS) .Spleen index, thymus index, phagocytosis rate and phagocytic index of peritoneal macrophages were assessed, and the spleen and thymus tissues were examined by histology.The percentage of CD3 +, CD4 +, and CD8 +cells in peripheral blood were determined by flow cytometry.Results APS significantly increased the thymus and spleen indexes in both immunosuppressed mice and normal mice, promoted the histological development of spleen and thy-mus in normal mice, enhanced the recovery of histological structures in the spleen and thymus in the CTX-induced immuno-suppressed mice.APS also enhanced the phagocytosis rate and phagocytic index of peritoneal macrophages in both immuno-suppressed mice and normal mice.In addition, the percentage of CD3 +and CD4 +cells,the ratio of CD4 +/CD8 +in pe-ripheral blood of both CTX-induced immunosuppressed mice and normal mice were increased while CD8 +cells were de-creased.Conclusions The results of this study suggest that astragalus polysaccharide can improve the non-specific immu-nity and cellular immunity in mice, and indicate that we established comprehensive evaluation indexes of immunoregulatory effects of polysaccharides.
6.Staining Improvement for Blastocystis hominis Specimen
Ruiqi ZHANG ; Houbiao CHEN ; Huiping WEI ; Shuilian SU
Chinese Journal of Parasitology and Parasitic Diseases 1997;0(06):-
Schaudinn solution was used to fix the Blastocystis hominis specimen and an improved Harris hematoxylin staining was applied to stain it.The method shows clearer internal structure of the parasite, simpler and less timeconsuming than the traditional iron hematoxylin solution.
7.Clinical Efficacy of Yiqi Huoxue Decoction in the Treatment of Children with Spleen and Kidney Deficiency Type Nephrotic Syndrome
Chunshui DA ; Hong GAO ; Hong ZHANG ; Ruiqi HAI ; Wenshan QIAO
Progress in Modern Biomedicine 2017;17(26):5087-5090
Objective:To study the clinical efficacy ofYiqi Huoxue Decoction in the treatment of children with spleen and kidney deficiency type nephrotic syndrome.Methods:A total of 80 children with spleen and kidney deficiency type nephrotic syndrome in our hospital from June 2014 to October 2016 were enrolled in this study.The subjects were divided into control group (n=40) and treatment group (n=40) according to the random number table method.The control group was treated with prednisone,and the treatment group was treated with prednisone combined with Yiqi Huoxue Decoction,the two groups were treated for 4 months.The clinical efficacy of the two groups were evaluate.The 24h proteinuria,total cholesterol (TC),plasma albumin (Alb),and renal function parameters including blood urea nitrogen (BUN),serum creatinine (Scr),and serum creatinine clearance (Ccr) of the two groups before and after treatment were compared.Results:The total effective rate of the treatment group was 95.00%,which was significantly higher than 67.50% of the control group,the difference was statistically significant (P<0.05).The 24h proteinuria,TC,BUN and Scr of the two groups after treatment were significantly lower than before treatment,the Alb,Ccr of the two groups were significantly higher than before treatment,and above indexes in treatment group were better than the control group,the differences were statistically significant (P<0.05).Conclusion:Yiqi Huoxue Decoction have good clinical efficacy in the treatment of children with spleen and kidney deficiency type nephrotic syndrome,which can obviously improve children renal function,and is worthy of clinical application.
8.Discussion of the Teaching Way of Emerging Infectious Diseases
Wensheng XU ; Junxue WANG ; Wu NI ; Ruiqi ZHANG
Chinese Journal of Medical Education Research 2006;0(11):-
In the course of emerging infectious disease learning,comprehensive methods including comparing the similarity of emerging infectious disease and classical infectious disease,uniting the general introduction and the typical examples explanation,strengthening the multimedia teaching and the case based teaching were adopted to strengthen the effect of teaching.
9.Evaluation of bone marrow mesenchymal stem cells for the treatment of osteonecrosis of femoral head
Ruiqi LI ; Guoping ZHANG ; Lizhong REN ; Yali LI ; Yajun Lü
Chinese Journal of Tissue Engineering Research 2013;(35):6327-6332
BACKGROUND:There are various methods for the treatment of osteonecrosis of femoral head, but there is no satisfactory method to promote the repair of osteonecrosis of femoral head. In recent years, bone marrow
mesenchymal stem cel transplantation for the treatment of osteonecrosis of femoral head has achieved certain effect.
OBJECTIVE:To review the application progress and problems of bone marrow mesenchymal stem cel transplantation for the treatment of osteonecrosis of femoral head.
METHODS:A computer-based online search was performed in PubMed database, Wanfang database and CNKI database for the related articles from 1999 to 2012. The articles on the isolation, culture, differentiation, labeling and in vivo tracing of bone marrow mesenchymal stem cel s were selected, as wel as the basic and clinical
researches on bone marrow mesenchymal stem cel transplantation for the treatment of osteonecrosis of femoral head. A total of 39 articles were included for review.
RESUTLS AND CONCLUSION:At present, the method for the isolation of bone marrow mesenchymal stem cel s includes adherence screening method, density gradient centrifugation, flow cytometry separation and magnetic activated cel sorting method;the commonly used method for cel labeling and tracing includes isotope tracing method, antigen labeling method, antigen labeling, fluorescent labeling and MRI contrast enhancer labeling
method. The method for the treatment of osteonecrosis of femoral head with bone marrow mesenchymal stem cel s includes pith dril ing decompression combined with bone marrow mesenchymal stem cel injection and
transplantation, intervention plus bone marrow mesenchymal stem cel transplantation, gene transfection combined with bone marrow mesenchymal stem cel transplantation and tissue engineering technology of bone marrow mesenchymal stem cel s. Although, the research on the bone marrow mesenchymal stem cel transplantation for the treatment of
osteonecrosis of femoral head has achieved great progress, there are stil problems needed to be further solved.
10.Correlation between connexin37 C1019T polymorphism and ischemic stroke and its outcome
Dan LIU ; Jiangong SUN ; Hongying SUN ; Guangwei ZHANG ; Jia ZHANG ; Guixi WANG ; Jing YANG ; Ruiqi SONG
International Journal of Cerebrovascular Diseases 2012;20(4):251-256
Objective To investigate the correlation between cornexin37 (Cx37) CI019T polymorphism and ischemic stroke and its outcome.Methods Restriction fragment length polymorphism analysis was used to detect the distribution of Cx37 C1019T polymorphism in a ischemic stroke group and a control group.The modified Rankin scale (mRS) was used to evaluate the neurological outcome at 3 months after onset.Results A total of 235 patients in the control group,and 232 patients in the ischemic stroke goup were recruited.In the ischemic stroke group,210 had a good outcome (mRS <3) and 22 had a poor outcome (mRS≥ 3).The TT genotype (12.93% vs.6.39% ; x2 =10.087,P =0.006) and T allele (31.25% vs.21.49% ; x2 =11.466,P=0.001) frequency in the ischemic stroke group were significantly higher than those in the control group.Multivariatelogistic regression analysis showed that TT genotype (odds ratio [OR] 5.794; 95% confidence interval [CI] 1.405-23.894; P =0.015) and T allele (OR 131.016,95% CI 6.943 -2 472.477; P =0.001)signifkantly increased the risk of ischemic stroke.Univariate analysis showed that TT genotype (OR 0.650,95% CI 0.144 - 2,934; P =0.575),CT genotype (OR 0.622,95% CI 0.234 - 1.655; P =0.342),and CC genotype (OR 0.654,95% CI 0.268 - 1.595; P =0.350) had no significant correlation with the outcome of ischemic stroke.Conclusions Cx37 1019TT genotype and T allele may increase the risk of ischemic stroke.T allele is one of genetic susceptibility factors for ischemic stroke; however,its gene polymorphism is not associated with the outcome of ischemic stroke at 3 months after onset.